本文選題：灌注加權(quán)成像　切入點(diǎn)：動(dòng)態(tài)對(duì)比增強(qiáng)　出處：《遵義醫(yī)學(xué)院》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：目的:通過對(duì)前列腺良惡性疾病患者行常規(guī)磁共振成像(magnetic resonance imaging,MRI)、動(dòng)態(tài)對(duì)比增強(qiáng)(dynamic contrast enhanced,DCE)及磁共振波譜成像(magnetic resonance spectroscopy,MRS)掃描,探討DCE灌注參數(shù)、MRS在前列腺癌(prostate cancer,PCa)診斷中的應(yīng)用價(jià)值以及前列腺特異性抗原之比與DCE灌注參數(shù)、MRS的相關(guān)性。方法:收集經(jīng)病理或診斷性治療證實(shí)的非PCa患者25例(其中單純良性前列腺增生患者17例,良性前列腺增生合并炎癥患者8例)、病理或隨訪證實(shí)的PCa患者16例、正常健康志愿者對(duì)照組20例,均行常規(guī)前列腺M(fèi)RI、DCE、MRS檢查。所有患者及健康志愿者掃描前均檢測(cè)血清總前列腺特異性抗原(total prostate specific antigen,T-PSA)、血清游離前列腺特異性抗原(Free prostate specific antigen,F-PSA)。結(jié)果:1.PCa組、非PCa組、正常對(duì)照組三組的T-PSA值分別為(52.60±103.26ng/m L)、(15.09±9.75ng/m L)、(2.46±0.68ng/m L);各組的F-PSA值分別為(4.56±3.48ng/m L)、(2.08±1.15ng/m L)、(0.59±0.16ng/m L);各組的F/T-PSA值分別為(0.18±0.08)、(0.15±0.05)、(0.24±0.04);2.各組的K~trans值分別為(0.19±0.07min-1)、(0.11±0.03min-1)、(0.06±0.02min-1),組間差異及兩兩比較均有統(tǒng)計(jì)學(xué)意義(P0.05);3.各組的Kep值分別為(1.06±0.13min-1)、(0.73±0.19min-1)、(0.63±0.11min-1),組間差異及兩兩比較均有統(tǒng)計(jì)學(xué)意義(P0.05);4.各組的Ve值分別為(0.17±0.07)、(0.11±0.04)、(0.10±0.03),組間差異有統(tǒng)計(jì)學(xué)意義(P0.05),兩兩比較,PCa組和各組間差異均有統(tǒng)計(jì)學(xué)意義(P0.05),而非PCa組與正常對(duì)照組間差異無統(tǒng)計(jì)學(xué)意義(P0.05);5.K~trans、Kep、Ve診斷PCa的最佳閾值分別為0.14min-1、0.925min-1、0.145。6.PCa組、非PCa組、正常對(duì)照組三組的(Cho+Cr)/Cit值分別為(5.17±3.68)、(0.70±0.43)、(0.37±0.47),組間差異及兩兩比較均有統(tǒng)計(jì)學(xué)意義(P0.05)。7.PCa組與非PCa組的F/T-PSA與K~trans、Kep、Ve、(Cho+Cr)/Cit值之間的相關(guān)系數(shù)r分別為0.038(P0.05)、0.05(P0.05)、-0.013(P0.05)、0.338(P0.05)。結(jié)論:1.DCE、MRS均對(duì)PCa有重要的診斷及鑒別診斷價(jià)值;2.DCE灌注參數(shù)(K~trans、Kep、Ve)中,K~trans、Kep的診斷效能最高,K~trans的特異度較高,而Kep的敏感度較高,三者診斷前列腺癌的最佳閾值分別為0.14min-1、0.925min-1、0.145;3.F/T-PSA與(Cho+Cr)/Cit值之間存在較弱的正相關(guān)關(guān)系,與DCE灌注參數(shù)之間均無明顯相關(guān)性。
[Abstract]:Objective: to study the clinical features of benign and malignant prostatic diseases (BPH) by routine magnetic resonance imaging (MRI), dynamic contrast enhanced resonance (DCE) and magnetic resonance spectrum imaging (MRS). To investigate the value of DCE perfusion parameter Mrs in the diagnosis of prostate cancer in prostate cancer and the correlation between the ratio of prostate specific antigen and DCE perfusion parameter Mrs. Methods: 25 cases of non-PCa patients confirmed by pathological or diagnostic treatment were collected. (among them, 17 patients with simple benign prostatic hyperplasia, There were 8 cases of benign prostatic hyperplasia complicated with inflammation, 16 cases of PCa confirmed by pathology or follow-up, and 20 cases of normal control group. All patients and healthy volunteers were examined for total prostate specific antigenase T-PSAA and free prostate specific antigen-F-PSAA before scanning. Results the results showed that the serum total prostate specific antigenase T-PSAA and free prostate specific antigen-PSAA were detected in all patients and healthy volunteers before scanning. Results the results showed that the serum total prostate specific antigen-PSAA and free prostate specific antigen-PSAA were detected in all patients and healthy volunteers before scanning. Results: 1. The T-PSA values of the normal control group were 52.60 鹵103.26ngmL / L = 15.09 鹵9.75ngmL / L = 2.46 鹵0.68ng / mL, respectively, and the F-PSA values of each group were 4.56 鹵3.48ngm / L / L = 4.56 鹵3.48ngm / L = 2.08 鹵1.15ngmL / L = 0.59 鹵0.16ngm / L, respectively. The F-PSA value of each group was 0.18 鹵0.08ngmL / L = 0.24 鹵0.04ngL / L respectively. The K#en0# of each group was 0.19 鹵0.07min-1n-1 + 0.03min-1 鹵0.06 鹵0.02min-1 respectively, and the difference between the two groups was statistically significant (P < 0.05). The difference between the two groups was statistically significant (P 0.05). The value of ve in each group was 0.17 鹵0.07 鹵0.04 鹵0.010 鹵0.03, there was significant difference between the two groups (P 0.05), and the difference between the two groups was statistically significant, while the difference between the two groups was significant (P 0.05), while that in the non-PCA group was significantly higher than that in the normal control group (P < 0.05), while that in the non-PCA group was significantly higher than that in the normal control group (P < 0.05), and the difference between the two groups was statistically significant (P < 0.01), while that in the non-PCA group was significantly higher than that in the normal control group (P < 0.05). There was no significant difference between the two groups. The optimal threshold for the diagnosis of PCa was 0.14min-1ng 0.925min-1 + 0.145.6.PCa, respectively. Non PCa group, The values of Cho Cr)/Cit in the normal control group were 5.17 鹵3.68, 0.70 鹵0.43, 0.37 鹵0.47, respectively. There were significant differences between the two groups (P0.050.7.The correlation coefficient r between the FT-PSA and the Cr)/Cit value of the PCa group and the non-#en1# group were 0.038 鹵3.68, P 0.05- 0.013, P 0.0338P0.05and 0.338P0.05respectively). Conclusion\\\;\\\%\\%\\%\%\%\%\%\%\%\%\%\%\%\%\% of PCa? The diagnostic value 2. The diagnostic efficacy of KTX Kep was higher than that of Ktrans in DCE perfusion parameters. 2. The specificity of Ktranstrans Kep was higher in DCE perfusion parameters (P < 0.05), and the specificity of KtransKep was higher than that of KtransKep. However, the sensitivity of Kep was higher, and the best threshold for diagnosis of prostate cancer was 0.14min-1n 0.925min-1U 0.145min -0.145t. There was a weak positive correlation between T-PSA and DCE Cr)/Cit, but there was no significant correlation between DCE perfusion parameters and T-PSA.
【學(xué)位授予單位】：遵義醫(yī)學(xué)院
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R445.2;R737.25

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 謝長(zhǎng)青,盧曼麗,吳光耀;腦組織質(zhì)子磁共振波譜成像[J];武漢大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2003年04期

2 徐凱,錢勇先,林家瑞,金德勤;快速磁共振波譜成像的研究進(jìn)展[J];生物醫(yī)學(xué)工程學(xué)雜志;2004年04期

3 黃敏;盧松濤;;磁共振波譜成像技術(shù)的研究現(xiàn)狀及發(fā)展趨勢(shì)[J];生物醫(yī)學(xué)工程研究;2006年02期

4 徐惠;李傳福;厲保秋;任慶國(guó);張曉明;于紅鸞;;磁共振波譜成像在食蟹猴腦研究中的應(yīng)用[J];山東大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2010年10期

5 田鐵橋;張琥;劉波;;影響頸髓磁共振波譜成像質(zhì)量因素分析[J];山西醫(yī)藥雜志;2011年08期

6 周麗;李晨曦;解燕昭;劉青蕊;;磁共振波譜成像技術(shù)在中樞神經(jīng)系統(tǒng)疾病中的臨床應(yīng)用[J];現(xiàn)代電生理學(xué)雜志;2012年04期

7 孫家棟;;磁共振波譜成像技術(shù)在中樞神經(jīng)系統(tǒng)疾病診斷中的臨床應(yīng)用[J];中國(guó)醫(yī)療設(shè)備;2013年07期

8 徐凱,詹應(yīng)鍵,林家瑞,金德勤;奇異值分解在磁共振波譜成像中的應(yīng)用[J];上海生物醫(yī)學(xué)工程;2003年03期

9 葉偉;于明琨;;磁共振波譜成像在神經(jīng)外科的應(yīng)用[J];中國(guó)組織工程研究與臨床康復(fù);2009年04期

10 于春雨;耿德勤;;磁共振波譜成像在神經(jīng)系統(tǒng)疾病早期診斷中的應(yīng)用研究進(jìn)展[J];徐州醫(yī)學(xué)院學(xué)報(bào);2010年04期

相關(guān)會(huì)議論文 前5條

1 黃勇;劉克;李志銘;;二維和三維磁共振波譜成像技術(shù)在頭部掃描的臨床應(yīng)用[A];2010中華醫(yī)學(xué)會(huì)影像技術(shù)分會(huì)第十八次全國(guó)學(xué)術(shù)大會(huì)論文集[C];2010年

2 黃敏;盧松濤;詹應(yīng)建;林家瑞;金德勤;;基于相位編碼和靈敏度編碼的磁共振波譜成像技術(shù)及重建方法比較[A];中國(guó)生物醫(yī)學(xué)工程學(xué)會(huì)第六次會(huì)員代表大會(huì)暨學(xué)術(shù)會(huì)議論文摘要匯編[C];2004年

3 陳雁;余小多;申皓;歐陽漢;周純武;;育齡期女性子宮的3D 1H磁共振波譜成像[A];中華醫(yī)學(xué)會(huì)第16次全國(guó)放射學(xué)學(xué)術(shù)大會(huì)論文匯編[C];2009年

4 葉偉;于明琨;;磁共振波譜成像在中腦損傷預(yù)后判斷中的價(jià)值[A];第七屆全國(guó)創(chuàng)傷學(xué)術(shù)會(huì)議暨2009海峽兩岸創(chuàng)傷醫(yī)學(xué)論壇論文匯編[C];2009年

5 張獻(xiàn)文;況時(shí)祥;李王杏安;;磁共振波譜成像檢測(cè)VD大鼠海馬區(qū)神經(jīng)元、膠質(zhì)細(xì)胞的代謝及腦通湯的干預(yù)作用[A];貴州省第六屆中西醫(yī)結(jié)合神經(jīng)科學(xué)術(shù)年會(huì)論文匯編[C];2013年

相關(guān)博士學(xué)位論文 前2條

1 姜興岳;磁共振波譜成像及磁共振彌散張量成像在外傷性腦損傷的應(yīng)用研究[D];復(fù)旦大學(xué);2007年

2 黃敏;并行磁共振波譜成像理論及圖像重建方法研究[D];華中科技大學(xué);2005年

相關(guān)碩士學(xué)位論文 前4條

1 蒲艷;磁共振波譜成像診斷輕微型肝性腦病的探討[D];昆明醫(yī)科大學(xué);2015年

2 張世斌;磁共振波譜成像在腦小血管病患者半卵圓中心影像研究中的應(yīng)用[D];華北理工大學(xué);2015年

3 李勇;灌注加權(quán)成像定量參數(shù)及磁共振波譜成像診斷前列腺癌的價(jià)值[D];遵義醫(yī)學(xué)院;2017年

4 張振光;大鼠面神經(jīng)損傷后面神經(jīng)核團(tuán)神經(jīng)元凋亡的磁共振波譜成像研究[D];昆明醫(yī)學(xué)院;2011年

，

本文編號(hào)：1595755